A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis

  • J Am Acad Dermatol. 2021 Apr;84(4):1160-1162. doi: 10.1016/j.jaad.2020.07.122.
Yoo Jung Kim  1 ,  Elena Schiopu  2 ,  Katalin Dankó  3 ,  Tahseen Mozaffar  4 ,  Srinivas Chunduru  5 ,  Kirstin Lees  5 ,  Namita A Goyal  4 ,  Jeffrey Sarazin  2 ,  David F Fiorentino  6 ,  Kavita Y Sarin  7
Affiliations
  • 1. Department of Dermatology, Stanford University School of Medicine, Redwood City, California.
  • 2. Department of Rheumatology, University of Michigan, Ann Arbor, Michigan.
  • 3. Department of Clinical Immunology, Medical Faculty, University of Debrecen, Debrecen, Hungary.
  • 4. Department of Neurology, University of California Irvine, Irvine, California.
  • 5. Idera Pharmaceuticals, Inc, Exton, Pennsylvania.
  • 6. Department of Dermatology, Stanford University School of Medicine, Redwood City, California. Electronic address: [email protected].
  • 7. Department of Dermatology, Stanford University School of Medicine, Redwood City, California. Electronic address: [email protected].
PMID: 32781178 DOI: 10.1016/j.jaad.2020.07.122
Products